interesting - search results

If you're not happy with the results, please do another search

1 1003

The emergence of the cannabis industry has led to the creation of sub-industries within it and this has created numerous opportunities for investors.

One sub-industry we find to be very attractive is biotech and this is due to the potential development of numerous billion dollar products.

The potential medical benefits of cannabis can no longer be ignored as agencies like the National Cancer Institute (NCI) continue to recognize its potential. In 2015, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells.

Betting on Biotech

Although the biotech industry offers a lot of opportunity, it presents even more risk. When we look at biotech investment opportunities, we look for companies that possess a competitive or unique advantage over their peers.

Last week, one of the biotech companies we have been monitoring closely, Nemus Bioscience (NMUS), announced that it will be advancing the development of a human-dosage suppository formulation of NB1222 with Catalent Pharma Solutions. The product candidate is the proprietary prodrug of tetrahydrocannabinol (THC).

NB1222 has been synthetically manufactured and is being developed to treat and manage chemotherapy-induced nausea and vomiting (CINV). Nemus also plans on advancing this prodrug into formulation activity for the glaucoma indication using its NB1111 candidate molecule.

Today, Nemus signed a development agreement with United Kingdom-based Nanomerics to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, the active component of Nemus drug candidate NB1111 being developed for glaucoma.

The goal of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics.

According to the agreement, work will commence on a future date determined by Nemus. The date is expected to be related with its development plans and corporate objectives.

Nemus Bioscience CEO Brian Murphy said, “Should we find success in formulating NB1111 using Nanomerics’ MET, we could also examine its application using our proprietary Nemus ophthalmic analogue of CBD (NB2222). Our company objective is to establish strategic partnerships utilizing a diverse cannabinoid-based ocular platform to address multiple types of eye disease.”

A Stock to Watch

Nemus Bioscience is an interesting company to watch due to its valuation, product pipeline, and its strategic partnership with the University of Mississippi. The university has been the sole provider of cannabis for medical research through a partnership with the National Institutes of Health since 1968.

We are favorable on this update as it shows further execution by Nemus. The company’s strategic relationship with Federal agencies makes it an attractive opportunity for investors and a stock to watch.

1 4049

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 9907
cbd stocks

List Of CBD Stocks To Watch

For a fairly new market, the Marijuana industry has been embracing unprecedented levels of growth over the past decade. The surge had every investor frantically logging in to their e-trade accounts trying to find the next big Marijuana stock. Although the previous focus of the medical companies was based on the harvesting of the THC component of Marijuana, many have recently discovered the true health benefits of Cannabidiol; a part of the plant that only holds its health benefits and not those that get you ‘high’.

cbd stocks

The recent deregulation and legalization patterns that every state has been following over the past decade are only a testament to how close the United States is to nation-wide legalization. In addition to the whopping 23 states who have already legalized marijuana, there are 15 other states that have legalized the sale of medicinal.

Marijuana businesses in Colorado, which voted to legalize the drug recreationally in 2012, reported about $1.1 billion in legal sales of medical and recreational marijuana and related products last year through the month of October, according to the tax data from the state’s Department of Revenue. That number easily tops the roughly $996 million in total marijuana revenue the state reported in 2015. With this has come an increase in awareness across the board and one of the hottest topics right now has been CBD.  Based on the attention the industry is getting, it seems fitting to highlight some of the most active CBD stocks to watch this year. Here are several CBD stocks on our own list:

Ubiquitech Software Corp (UBQU)

Ubiquitech Software Corp’s main subsidiary, focuses on the sale of CBD products through their network of International growers.

This week the company released earnings guidance for the quarter giving high expectations for year over year growth. Management is anticipating a 50% increase in revenue for the quarter compared to last year.

The company anticipates that revenues for the quarter ended February 28, 2017 will increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000. The revenue growth is due primarily to the continued acceptance and increased exposure of the HempLife Today™ product line.

“We are excited to show what we have achieved over the past few years,” said James Ballas, CEO, “and we pride ourselves on our process of delivering a superior product at a cost that makes our products available to the widest possible audience. Because, it is this process that makes our company continue to grow.”

This is in addition to the growth that the company has seen already. Earlier this year, UBQU announced its fourth quarter and fiscal year end 2016 financial results. Revenues for the quarter increased to $1,225,015 and to $3,493,113 for the year. Earnings increased 840% from the previous year to $334,350 from $39,651 in 2015. To date, the stock has jumped as high as $0.04 and is now trading in a channel nearly 50% higher than where it was trading at toward the beginning of the year. Considering the last two financial related announcements discussed noticeable growth, this could be the trend to watch for with this company in 2017.

Corbus pharma(CRBP)

Corbus Pharma actually has no direct engagement with medical or recreational marijuana sales. They are focused on developing a non-psychoactive synthetic drug that imitates the health benefits caused by the bodies reaction to CBD, Resunab. Currently in phase 3 testing, the drug is said to be release in 2019 and will be a huge driver for this $400-million cap company.

Over the last 3 months Corbus stock price has been experiencing volatile movements, dropping to 6.4 dollars in mid-February. However, the stock has been steadily increasing since. Corbus could be a good purchase because of its inelasticity to the stock prices of other marijuana stocks after possible government regulation. This offers a level of diversity which could prove to be extremely advantageous especially with the change of government in November.

mCig, Inc. (MCIG)

Since it was trading around 2 and a half cents in September, MCIG has seen highs of as much as $0.505.  The stock has been upholding a channel roughly between $0.30 and $0.40 for the last few weeks and multiple announcements show, in our opinion, that company’s focus on building shareholder value including triple digit sales growth, canceling 20 million shares  and converting another 60 million shares into preferred that also carry with it a 2 year lock up.  The company has also announced that it will be reporting on its “record financial growth numbers and cost basis investments; to include, Vapolution, VitaCBD, Omni Health (OTC PINK: OMHE,) Agri-Contractors, and other strategic partnerships.”

This week MCIG filed its 3rd Quarter financial reports showing significant growth for the company including:

  • Revenue increased 446% to $1,362,689 compared to $249,641
  • Gross profit increased 239% to $288,230 compared to $85,076
  • Expenses decreased 27% to $97,052 compared to $133,236
  • Cash and cash equivalents increased 422% to $420,888 compared to $80,542
  • Current assets increased 1,241% to $1,259,689 compared to $93,930

Cara Therapeutics(CARA)

Founded in 2004, Cara therapeutics was an interesting stock to watch over the past year. They are currently in the preclinical trials of creating a CBD compound that can be used for treating neuropathic and inflammatory pains, a market usually only tainted with opioids.

Despite their stock price drop over 62 percent in 2016, Cara has been steadily climbing since, in the first 2 months of 2017 the stock price managed to skyrocket by 186% ($9-$16.72). Their recent expansions into the pain-relief industry could become a huge catalyst for their growth, especially as the market starts to accept CBD as a healthier alternative to addictive opiate-based painkillers.

Advantis Corp. (ADVT)

We started watching Advantis Corp. (ADVT)  last summer. There’s enough going on here in our opinion to take notice of including the recent announcements that the company has taken steps to become a fully-reporting public company as well as launched distribution of topical cannabis roll-on and Tinctures to treat pain conditions. This also comes as the company has begun to further expand on its overall product offering so just like we cited at first “way back when” with Totally Hemp Crazy, we think that ADVT could be another company to follow during its infancy.  Since we picked back up on this, we’ve also watched as ADVT climbed from around $0.005 to highs of $0.035 during the last full week of February.

This week the company announced that it has received the first orders for Hemperor’s Club, Elixicure and Deltacure products from California’s largest medical marijuana delivery service, Speedweed. The delivery service has asked Advantis to participate as a Premiere Guest of Speedweed at the Cannabis Business Expo this week.

Insys therapeutics (INSY)

Insys therapeutics, is a specialty pharmaceutical company that has started their venture into the cannabis industry over the past year. Just recently the FDA green lit the pharmaceutical giants reformulation of the longest standing marijuana based medicine, marinol. Originally created by ABBvie incorporation, the reformulated medicine (Now syndros) is an effective and healthy way to treat millions of cancer patients who suffer from nausea from Chemotherapy sessions, Also doubling as a treatment for the lack of appetite in aids patients. According to studies done by Insys, Sydros is said to eventually generate peak annual sales of roughly 200 million dollars, only 20 million dollars less than their top selling opioid painkiller Subsys.

Although the stock price hit a trough in the middle of December of 2016 due to an ongoing court case, It a poised them for growth in the next year. While there still hasn’t been a definite outcome in the settlement of the cases, The Small-Cap pharmaceutical companies’ price has steadily been increasing since the incident. Their new change in management combined with their recent developments in the cancer relief industry might prove them to be an extremely interesting stock to watch in 2017.

Gw Pharma (GWPH)

Judging by the fact that you are reading this article, chances are that you have heard about the next stock, British medical marijuana giant GW pharma. Founded in 1998, The English pharmaceutical company has been specializing in creating CBD-based prescription medicines for their widespread international consumers. The company’s Key product is Sati vex, an oromucosal spray for the treatment of cancer pain, Multiple Sclerosis and neuropathic pain. Just recently, GW pharma submitted their request to formulate medicine Epidiolex, Created to treat the 2 million people who suffer from epilepsy in the united states. This vast consumer base has set projected peak annual sales from $300 million to $3 Billion. The main question at hand is whether they will be able to maintain this level of steady growth. Although the price had been stagnant, following a small decrease in price a month ago the stock has been steadily increasing, The true results will begin to shine as they begin to sell their breakthrough medicine, Epidiolex.

AbbVie (ABBV)

Best known for their “miracle” arthritis drug Humira (The top Selling drug in the world), their new developments into the CBD industry will prove to be something to monitor for the growth of this company’s market cap. Their latest cancer-relief medicine Venclexta, is projected to reap in at least 1.5 billion dollar’s worth of annual sales in the next year.

Like most companies in the Medicinal Marijuana industry, AbbVie faced a giant drop in stock price in November because of regulation skepticism as a result of the election of United States President Donald Trump. They still, however, continue to grow their revenue and earnings by double digit numbers, not to mention an attractive dividend yield of 4.2%. Collectively with their relatively cheap stock price and their recent advances into the CBD and autoimmune industries, this stock will be very interesting to watch in 2017.

AXIM Biotech (AXIM)

Axim Biotech recently announced their plans of improving their patent for the worlds first CBD chewing gum. The small-cap pharmaceutical company decided to take an interesting approach to the widespread intake of CBD for medication purposes. Furthering their customer-base, AXIM has engaged in new studies to test the benefits of cannchew from IBS patients to sclerosis patients, this increase consumer base will be a huge driver in their performance in 2018.

Despite their growth over the past 2 years, AXIM is still not a profitable company, closing out 2016 with $870,000, just shy of their $1.5 million debt. Their stock price spiked in mid January after this announcement at the JP Morgan Health Care Conference, the stock then fell down to 9 dollars thereafter. Their execution of their strategies over the next year will be the real facilitator of the outcome of the companies overall success.

HEMP incorporated (HEMP)

HEMP Inc, longer standing marijuana/CBD stocks on this list is set on becoming the market leader in the widespread distribution and use of hemp products in the world. Although their prime focus was the prevalent cultivation of hemp, HEMP Inc. has enacted new plans to build over 500 acres of farm land, made simply for the production of CBD products, due to its continuously widespread legal adaptation across the united states.

Due to their experience in the industry, their ventures will mostly be a product of their established market presence in our opinion. One thing to keep watch on are the fraud claims that have been filed against HEMP Inc. CEO, Bruce Perlowin. The stock price took a hit just days after President Trump’s secretary Spicer gave his remarks about the future of legal marijuana. Despite this temporary downfall, HEMP continues to stay the course, trading between $0.03 and $0.04 during early March.

Zynerba Pharmaceuticals (ZYNE)

Founded in 2007, Zynerba pharmaceuticals have developed a steady focus in commercializing the widespread use of synthetic cannabinoids through transdermal(skin) delivery. The company is currently studying their product ZYN001 which target Fibrositis and neuritis patients, two epidemics that generate over 6 million cases in the United States alone. The CBD is delivered through a patch that is intended for application to the back, arm and thigh.

In mid-January, Zynerba announced that they will be selling 2.8 million shares at a 25% discount of the original $22.4 in order to raise money for the phase 3 development of their products. The trajectory of this firm will most likely be based on how quickly they receive acceptance from the FDA (projected Q1 of 2018) and the overall performance of their new products on the market. As of today, The stock price has been steadily increasing and has actually reached its highest point on February 15th.

Obviously these are just a few of the CBD stocks to watch but will be a list that we’ll continue to monitor and if necessary update.  If you’ve just come to, we’ve been covering the CBD industry specifically for the last few months considering its place in the legal arena.

Despite the recent negative reactions due to certain  statements made by the secretary of the White House we think the marijuana industry will continue to grow. The industry’s revenue increase in 2016 and the endless advantages green-states like Colorado have assumed since legalization are proof that Medicinal Marijuana is an industry that can provide great advantages.

The bright side in this is that traders can use these negative (government-caused) movements in the stock prices as methods to look at some of these stocks at lower levels. The recent medical findings in CBD research, have created an entire new sector to the Marijuana industry. Judging by its growth over the past 4 years, we think that this could prove to be one of the main drivers in its success.


Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 6 million restricted shares of Hemp, Inc. We may buy or sell additional shares of (HEMP, UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER.

0 1285

American Green Smart Vending System Unveiled to the Public on April 19th in Las Vegas at the Largest Machine Industry Event (NAMA) in America

American Green’s system is unique for three important reasons, all of which will be on display:

  • The market-leading interface is in use already and can be seen here: which many consider the most sophisticated operating system for smart retail currently available in the world.
  • American Green’s patent-protected process, created to enable the vending of controlled or age-restricted products has been designed to be ‘as good as a human.’
  • And lastly, to demonstrate the strength and versatility of American Green’s system, there will be machines from three manufacturers side by side, something that until now has not been seen in the relatively new market of smart vending combined with secure purchasing.

The biometric verification portion of the system is utilized by the US military and many large corporations who require top-notch security for identification prior to entering a facility. In addition to all of this, the entire system can be accessed via an app which allows remote purchasing in participating machines. Upon arrival at the physical machine, patrons login to their account, verify with the biometric control, and simply display the QR code on their smartphone to retrieve the product or products they purchased.

“American Green and our technology partner, PanPacific, have been working non-stop to improve this process for over four years now. The adoption of smart phones, familiarity with apps on those phones, and improvement in related vending technologies have now merged with a concept that the public could easily grasp before but are much more prepared to use now,” said David Gwyther, chairman and acting president at American Green. “Creating a process that allows flexibility in the machine selected by clients yet permitting verified accounts to login to the machines of any companies who choose to participate will grow adoption faster and simplify use by all parties. A baseball fan could buy a beer at the game in New York and cannabis from a dispensary in California the next day through the same app utilizing their verified account. This is a huge step forward for smart retail and the automated sale of regulated products,” Mr. Gwyther concluded.

In other news, the Company’s mobile app (available here: which can be shared with others and added to your phone’s screen, has been updated with a new survey. The new survey is focused on the use of smart vending for regulated purchases which should provide interesting and timely results for the NAMA show. The results of the first survey can be found here and will soon be visible on the company’s website at

Don’t Forget to Stop by American Green Store

Be sure to visit the Company Store for great American Green’s Amazon Store for clothing and apparel. Just click here: to get there. Also, find some of the finest CBD products at the company’s own store here: Also, click over to the company’s website at and sign up for the company’s EMAIL ALERTS to stay current on news. The company has over 6,600 shareholders and interest-holders on its private list and the list is growing every month. In addition, shareholders can join in the conversation about American Green here:


Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

0 1608

People always used to say that if you drank milk, it would help your bones grow. Well now, studies have showed that cannabis might have a similar impact. While people have been using cannabis for ages both medicinally and recreationally, only recently have the other effects of cannabis come to light. One of the most important development is the discovery of the “endocannabinoid system,” a collection of chemical pathways found in mammals whose existence wasn’t demonstrated until the 1990s.

This system is made of specific receptors that are affected by chemicals in our body-the endocannabinoids. Many of the chemicals in cannabis known as “phytocannabinoids”, are almost identical to the endocannabinoids present in our bodies. Therefore, the cannabis chemicals can also affect these receptors if they make their way into your bloodstream.

One of the most well-known chemical is THC (tetrahydrocannabinol) which creates the psychoactive “high” people desire when they use the drug for recreation. Other research has discovered other phtyocannabinoids that do not produce the psychoactive effect, but show therapeutic potential. The most prominent of these other chemicals is CBD (cannabidiol), which has been proven to show strong pain-relieving and anti-inflammatory properties, and also has been shown to essentially stop seizures caused by the neurologic condition Dravet’s Syndrome.

Scientists performed a study involving these chemicals to see how it affected broken femurs in laboratory rats. They found that CBD increased the strength of healed broken femurs. They found CBD to be most effective with other constituents removed. CBD increases the expression of a gene that results in a higher production of collagen, which creates harder bone material, a process named collagen cross-linking.
What is interesting is that, the CBD specifically has more therapeutic effect than the cannabis plant as a whole. Therefore, consuming canna

cannabis as a whole would not be nearly as effective as consuming the CBD itself. To be most effective a treatment would require the isolation or concentration of CBD and the removal or reduction of THC.
There is still much to be studied on this matter, but there are hopes that this could help strengthen human bones in the future.

0 1582

Cannabis has never been a “for-profit” industry in any country on earth; at least not until United States voters made it one. According to Gallup polls; the end of the cannabis prohibition seems almost inevitable considering a record 61 percent of Americans support legal adult use, but many questions remain unanswered. How will cannabis be sold and advertised? How will marijuana sales be regulated? Who will dominate the markets? Will weed be changed? If so, how? Finally, how do we know the legal sale of cannabis will not create a disaster?

These questions do not have simple answers, but CBSN set out to address them by traveling to Canada as well as five states and interviewing people on all sides of the issue from consumers to sellers, lobbyists to elected representatives. At one point Dan Riffle was one of the nation’s most influential activist for cannabis legalization. Riffle is now against what he views as a commercial takeover of the industry and the creation of a market which depends on marijuana abusers and children.

“Legalization is happening, you know, for the first and only time,” he said. “And it seems like instead we’re just going to do alcohol again. We’re just going to do tobacco again. We’re just going to create this big, commercial model.”

Once long-time supporter of legalization and professor of public policy at New York University; Mark Kleiman, shares Riffle’s concerns. “We’re lurching from prohibition to the most wide-open kind of legalization,” he said. “Probably a bad idea.”

Mason Tvert; Riffle’s former colleague at the Marijuana Policy Project, disagrees big time. Earl Blumenauer, a congressman from Oregon, and the leading voice for marijuana legalization nationwide also disagrees big time. They both argue that there is already a “Big Pot” –the Mexican drug cartels. They emphasize that what is actually frightening is not high profits and declining public health; rather criminal gangs selling a product that is not safe and the heartless criminal justice system putting people behind bars for consuming it.

“What’s scary is that we are destroying lives. What’s scary is we can’t protect children now. What’s scary is that we are subsidizing Mexican drug cartels,” Blumenauer said.

“What’s scary is that the unaccompanied minors that are flooding into the United States are here because of the disruption in Central America and the destabilization in Mexico. … African-American young men are four times more likely to be arrested or hassled for something that most Americans now think should be legal. Now those are things that are scary now! Those are things that are wrong now!”

Brendan Kennedy is an important person in the evolving landscape of legal pot as well as CEO of Privateer, a holding company for mainstream marijuana brands. He is the first marijuana entrepreneur to get over $100 million from investors including backers in Facebook, Spotify and SpaceX. He desires for Americans to trust him to sell weed responsibly.

Kennedy answered questions such as “Is there a trade-off in this industry between profits and public health?” and “Does it concern you that according to federal data, over 4 million Americans meet the criteria for cannabis abuse or dependence?”

Kennedy believes cannabis consumers will benefit because they will have access to a safer and better regulated product. He also feels that consumers of marijuana will benefit from access to a wider variety of cannabis-based products.

“I think that most people in the United States who want to consume cannabis are already consuming it,” he said. “It will be interesting to see how the different products lower the percentage of people who actually consume via smoke. I think we’ll see other form factors that will be far more appealing from a health perspective than actually smoking cannabis. … I know more than a dozen elite athletes who consume cannabis. But they’re not consuming a joint. They’re vaporizing. They’re using cannabis as a topical for sore muscles.”

0 687

Early this morning Arcturus GrowthStar Technologies (TSX: AGS, OTC: AGSTF) announced an LOI to purchase a farm in the great state of Florida that produces ornamental plants which are basically flowers, trees, fruits, vegetables etc. It’s actually a huge business down here and there’s definitely a significant demand for that. Now, you might be thinking why would a company in Canada take steps to buy a farm in Florida, when they can buy a farm anywhere else they wanted to? Let’s play devils advocate for a second and say that the CEO Bill Gildea really likes Orchids & Lilly’s and he loves a farm that is operating in the black, ie making money at a profit. Arcturus specialized in Controlled Environmental Agriculture (CEA) which is a fancy way of saying that they can increase yields of flowers, vegetables, or Cannabis by doing a bunch of sciency stuff I won’t bore you with; think hydroponics, aeroponics and most importantly vertical farming.

I reached out to the company this morning to ask one very important question; How does the current facility have their greenhouse configured? Is it flat tables with plants or is it racked layers that are vertical? The answer was that the current layout in the greenhouse is one that is entirely FLAT. So, if AGS just wants to be in the ornamental flower game they can take a farm that is doing $400,000 in profit, $2,600,000 in revenue and on the conservative side triple the yield with CEA tech to $1.2 million in profit, or $7,800,000 in revenue or on the realistic end quadruple output to $1.6m profit and $10.4m in revenue. One important thing to note, CEA is efficient and cost effective which will mean that there is likely more of a profit margin and the elimination of redundancies with regards to personnel. Making even the purchase of an Ornamental farm a profitable endeavor.

Now let’s talk about the part of the PR that said “zoned for cannabis or fits the criteria for cultivation in Florida.” In case you do not already know, Florida’s ballot 2 initiative comes with a few strings attached, the biggest one being that anyone that wanted to produce cannabis via license had to be in the agriculture business for at least 30 years; this farm has been in operation since 1959. The 30 year’s in business has been a non-starter for many people going after the 6 auctioned off licenses, not to mention the insane capital needed for those first 6. The good news is, 6 groups will not be able to meet production for the state and with the passage of Amendment 2 this will definitely change. Also, I know a few Canadian Companies that are already LP’s gunning for Florida, which is interesting. Getting into Florida first ahead of all the states on the west coast seems like a smart move, plus Florida has great weather for cultivation of cannabis (so I’ve heard). Either way, I’m sure we will get more details on what AGS is planning, specifically from John Sweeney who use to be the VP of Operation of the Tilray facility. That facility is 60,000 square feet and owned by Privateer holdings (owners of Leafly, Marley Natural etc). Hopefully Tuesday ends up being a good news day for Florida, Nevada and California, because I’m sure we will be hearing from people like John Sweeney much more. FYI polling data shows that Florida’s Amendment 2 is polling at 73% in favor, it needs 60% (super majority) to pass, California is looking good and Nevada is very close, but pulling towards passing…

0 1342

We wanted to share this press release with everyone since the #PotStock craze is in full swing, especially with the elections on Tuesday. VPRB has an interesting story because of one glaring factor. That factor being it recently acquired the entire asset base of Vapor Corp (VPCO) in August of this year. VPCO has/had annual revenues around $4,000,000, and also up-listed to the Nasdaq in 2014.

Unfortunately shortly before the up-listing the management team left the company it built up and Vapor Corp’s new team decided to make heavy investments into brick and mortar vape shops, which did not go well for them. As many companies put into a bind have done, they took on very bad toxic debt. Despite the fact that the business was still generating revenue, the publicly traded stock never recovered and it became an acquisition target. 

So here’s why this is interesting: The person that built this company before its epic fall is the CEO of VPRB. The company has zero toxic debt, is tightly held and clearly knows the business. This is a story that we’ve been following and we encourage everyone to read the shareholder update we’ve been waiting for. 

FT LAUDERDALE, FL / ACCESSWIRE / November 3, 2016 / VPR Brands, LP (VPRB) on behalf of the company, I am pleased to give our shareholders a 90-day corporate update regarding the recent acquisition of the wholesale operations and assets of Vapor Corp (VPCO). We are excited to inform our shareholders that the transition of our management and business operations are proceeding on schedule. The Companys wholesale division, along with current product lines have never stopped generating revenue since we took over. The transition has been seamless and this is partly due to the fact that we kept many of the former employees and sales associates on board, while strategically lowering costs by eliminating corporate redundancies and creating a business culture that is efficient and fiscally responsible.

On the corporate side, it is important to note that VPRB has no toxic debt. The company has a very low float of 2,343,816 and is widely held by insiders and management. Under my previous management we were able to uplist Vapor Corp from pink sheets all the way to the Nasdaq in 2014 just prior to my departure. Our management is again focused on building shareholder value while increasing sales and profit margins on our product lines.

The current brands under management are:

HoneyStick brand ( a premium open tank mod specifically designed and intended to be used for essential oils and which is becoming popular in medical and recreational marijuana legal states.

Vaporin brand ( is a high quality entry-level range of product sold nationwide in smoke shops, convenience stores and gas stations.

VaporX brand ( a premium mod and open tank system program for the experienced Vape customer all for under $100 and available at retail in custom display.

Hookah Stix brand Hookah flavor inspired cigalikes (which are electronic cigarettes designed to look as much as a tobacco cigarette as possible).

Helium brand ( the very first eliquid to be sold chilled to stay fresh in its unique customer counter top display chiller.

With regards to the legal Medical and Recreational cannabis markets we have heavy market penetration in California, Colorado, Oregon, Connecticut, and Minnesota as well as service and have accounts in Washington, Nevada, Michigan, New Mexico, Alaska, , Vermont‎, and Illinois.

Our products are sold in dispensaries with both private label and our flagship Honeystick brand. The Company has aligned with key partners in the states whether on the extraction or distribution side to service dispensaries within each market. We will be providing further updates on these partnerships, but expect our Co-branded items to be rolled into the market in Q4 2016.

As stated previously we are fully operational at the original Vapor Corp offices and warehouse‎ located at 3001 Griffin Rd, in Ft Lauderdale FL and have even negotiated a reduction in our monthly facility rent by 30% per month. The core team employed in the wholesale operation of Vapor Corp. have been integrated into VPR Brands, LP (VPRB) assuming similar roles in sales and logistics. This is important as it will preserve continuity in the business allowing for the preservation of current customer relationships. Additional continuity is being preserved because all the brands, trademarks, websites and customer accounts were also transferred over to VPR Brands. Integration has been going smoothly and the wholesale and distributor accounts are pleased to have original Vapor Corp management back‎ at the helm.

Vapor Corp name recognition, existing relationships with both suppliers and customers since 2008 is one of the longest running in the industry and is invaluable to VPR Brands, LP (VPRB). Vapor Corp has previously sold to over 25 of the countrys largest distributors and retail chain store customer and has existing vendor # ‘s with these accounts. It is our goal to reignite our business relationships with all the previous customers who helped make our products the most widely recognized in the industry. Under my previous management (of Vapor corp) sales peaked close to $25 million in 2014.

Although Vapor Corp was once among the strongest in the industry, previously reported revenues for their wholesale business dropped from a reported$1,889,777 in the first quarter of 2016 by approximately $520,000 to a reported $1,369,415 for the 2nd quarter ending Jul 31, 2016. Considering the acquisition of the Vapor Corp wholesale business occurred at the end of July 2016, VPR Brands will report only two months of acquired wholesale business in this coming 3rd quarter 2016. Prior to the acquisition, VPR Brands previously reported $61,526 in revenue for the 2nd quarter related to sales of its Helium brand e-liquid.

The timing of the acquisition of Vapor Corps wholesale business was also very important. Within the E-cigarette and vapor industry significant upheaval is occurring due to a change in regulatory treatment by the FDA of these products. The government had set August 8, 2016 as the cutoff date of any new product from being introduced at retail in the U.S. without first receiving premarket approval from the FDA. It is expected this provision will allow for products that were currently available prior to August 8, 2016 to remain in the marketplace likely through 2019. Considering that no new products are being allowed to come into the marketplace, current wholesalers, such as VPR Brands, are especially well-positioned to provide product to retailers and consumers via online assets.

There is a massive shift occurring in the market for electronic cigarettes and other related products. Where several years ago the major use of electronic cigarettes was as a replacement for traditional cigarettes, the prevalence of using electronic cigarette technologies for the consumption of cannabis is quickly sweeping the marketplace. Whether for traditional tobacco product use or as a delivery mechanism for either medical or recreational cannabis usage, there is simply no debate about the sheer size of this market and the growth the market has experienced. We are positioned to be a large part of this industry.


Kevin Frija CEO
VPR Brands, LP.

1 2446

WikiLeaks’ most current exposure of political emails displays the staff behind the scenes of Hillary Clinton’s presidential campaign made it a point to advise her on the issue of marijuana prior to a debate. It also reveals that the Clinton administration most likely will not make any notable changes to marijuana policy at the federal level. A preparatory document discovered in the hacked emails of Clinton’s campaign chairman, John Podesta, gives details on what Hillary was advised to say if she was asked whether she would legalize marijuana as the next leader of the free world.

“While YOU should avoid saying marijuana accounts for a signification portion of the U.S. correctional population or a significant portion of those behind bars for drug offenses, it IS correct that there are hundreds of thousands of arrests for marijuana crimes, and that there are thousands of people serving (some) time for marijuana crimes—many of whom would likely be better off in their communities,” the briefing reads.

The document then continues to explain that, with regard to nationwide marijuana reform, Clinton would most likely continue to follow President Obama’s “hands-off approach.”

“Like the Obama Administration’s current approach to the criminal enforcement of federal marijuana laws, YOU would not intervene in states that are reforming their own marijuana laws, as long as those states adhere to certain federal priorities,” the brief continues. “These priorities include not selling to minors, preventing inter-state transport of marijuana, and keeping organized crime out of the industry.”

Interestingly, however, the same collection of intercepted emails reveals that Hillary Clinton supports policies aimed toward the decriminalizing cannabis. Although the Democratic presidential candidate admits to being somewhat perplexed over how to achieve this concept at the national level.

“From my perspective, we do need to look hard at decriminalizing behavior that is not harmful, that is not leading to violence, and try to figure out how best to do that,” she said last year during a meeting with Black Lives Matters.

“I’m not sure exactly how you would implement it and how —you know, because remember, most of the laws you’re talking about are state and local laws,” Clinton continued. “I mean, the federal government can encourage, can make suggestions, can provide incentives, but most criminal law, most policing, all of the problems that we’ve been discussing are really controlled at the local and the state level. So you have to have a buy-in by others, not just by the federal government.”

0 2401

As a new cannabis patient in early 2014, Michael Bourque (Co-Founder and Inventor of the CannaCloud system) saw the need for industry improvements when first trying medical cannabis. He struggled with intimidation, confusion, and lots of unknowns in terms of strains, dosage, and frequency of use. He also struggled with the methods of inhaling from smoking to edibles to vaporizing. As an experienced machinist, CAD designer, and inventor, he went into his lab to start building a better way to consume medical cannabis. He machined components, 3D printed parts, disassembled other similar appliances, programmed microchip controllers, and experimented with various doses and strains of cannabis. Eventually, all these parts and components started working together and became the very first version of the high-tech CannaCloud vaporizer.

Then Michael started to think about what Keurig did in the coffee industry to add convenience and consistency to the single-serve coffee industry, and how that consumer business model could really help medical cannabis patients control their doses and help ensure they had a great experience every time they vaporized. So he set off to develop a pod-based vaporizing system, not just a vaporizer, along with experts from a variety of fields who joined him on his journey.

The original three partners founded CannaKorp, Inc. just north of Boston. The technology start-up’s goal is to simplify and improve the cannabis consumer experience. Their first product innovation is the world’s first pod-based vaporizing system, the CannaCloud™. The company has developed a new delivery method to provide unprecedented quality-assurance, convenience, and consistency. The CannaCloud and pods have gained mainstream attention because its modern design and easy operation are so appealing to the growing mainstream cannabis market. In addition, the pods are filled with natural cannabis flower creating a unique form factor that does not require additives or denaturing but does ensure cannabis’ “ensemble” effect is intact.

The cannabis industry is continuously evolving cultivation standards, packaging, quality validation, and dosing guidelines – which, in some ways, are still not meeting consumer demands. In order to meet those expectations, CannaKorp has developed the means to modernize and legitimize the way cannabis is grown, processed, packaged, sold, and consumed to enhance convenience and the overall experience for those mainstream consumers who seek benefits from this alternative medicine.

CannaKorp is partnering with leading, licensed cannabis cultivators, processors, and retailers to produce CannaCloud pods that meet our quality standards. This is the first-ever suite of proprietary products designed to deliver consumer satisfaction and help people achieve their personal wellness goals, all while being easy to use and a great experience.

CannaKorp is led by a highly experienced team with a track record of success and backed by experts in the industry. The management team includes three former Keurig executives, each of whom contributed to Keurig’s early success eventually leading to $5 billion in revenue. CannaKorp’s mission is to empower consumers to realize and embrace the benefits of cannabis. CannaCloud products are expected to be available in select markets in early 2017 and will then expand throughout the US and Canada.

In addition, CannaKorp is investing significant time and resources to create recyclable CannaCloud pods and packaging as social and environmental responsibility are an important part of CannaKorp’s core values. The team is working diligently to ensure our products and systems are environmentally friendly. CannaKorp will publish more detailed information as we progress and develop these plans and programs.

If you would like to learn more about CannaKorp, visit or you can reach them at 781.435.1812 or email You can also follow them on social media for daily updates and other interesting general information.

Fewer Pods v2

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
Ad Placements